Early Signal Diagnostics plans 10,000-patient AI cancer biomarker study in Bogotá

Early Signal Diagnostics will start a validation study in early 2027 at two laboratories in Bogotá, Colombia, enrolling about 10,000 patients to test whether its AI biomarker platform can detect ovarian and pancreatic cancer from capillary blood. The company says the study is designed to validate the technology in a diverse Latin American population and will report preliminary results about nine months after launch.

Why it matters: - Early Signal Diagnostics is trying to prove that AI cancer biomarkers can perform reliably in a real-world patient population, not just in development settings. - The study could help show whether the platform can detect ovarian and pancreatic cancer earlier from a simple capillary blood sample. - Testing in Bogotá also addresses a known gap in AI biomarker research: validation across diverse populations.

What happened: - Early Signal Diagnostics Corp said it will begin validation studies of its AI-driven biomarker platform in early 2027. - The study will run at two laboratories in Bogotá, Colombia. - About 10,000 local patients are expected to enroll. - The study will evaluate the platform’s ability to detect ovarian cancer and pancreatic cancer from a capillary blood sample.

The details: - The company wants AI biomarkers validated with the same rigor used for companion diagnostics. - Early Signal Diagnostics said the Latin American setting will help test performance across different patient groups. - The platform uses single-cell RNA sequencing analysis and machine learning for cancer biomarker discovery. - Recent analysis identified a novel set of oncogenes and tumor suppressor genes that were not previously recognized in pancreatic and ovarian cancer. - The company said those findings may point to actionable targets for therapeutic intervention. - The participating laboratories will be announced after agreements are finalized. - Preliminary results are expected about nine months after the validation studies begin. - The company is headquartered in Cathedral City, California. - Early Signal Diagnostics develops diagnostic tests for early disease detection. - The company combines single-cell RNA sequencing analysis and machine learning to identify biomarkers that may help clinicians find disease sooner. - More information is available in the company’s announcement.

Between the lines: - The Bogotá study gives Early Signal Diagnostics a chance to build credibility in a market outside the U.S. while also testing the platform on a broader patient base. - The scale of the trial suggests the company is aiming for evidence that could matter to clinicians, laboratories and potential partners. - Validation in a diverse population is especially important for AI-based diagnostics, where performance can shift when patient demographics change.

What's next: - Early Signal Diagnostics will finalize agreements with participating laboratories before naming them. - The company expects preliminary results roughly nine months after the study starts. - The outcome will help determine whether the platform can move closer to broader clinical use.